0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-275.94%PremiumMay 16, 2025Expiry Date3.67Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.41Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Nanoviricides Stock Discussion
First-Ever Broad-Spectrum Antiviral Could Combat Rising Measles Crisis, NanoViricides Reveals
Breakthrough Drug Ready to Fight Measles Crisis: NanoViricides Offers Emergency Solution
NanoViricides' Game-Changing Antiviral Shows Superior Results Against Multiple Viruses
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
Tuesday, 4th March at 6:30 am
SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us". He identifies an important issue that, "…there is no approved antiviral for those who may b...
Sadly, I'm gonna have to close this position.
Pre-revenue stage increases reliance on grants and other federal funding.
Tariff increases risk increasing COGS by 18-22%.
Capital structure will require dilutive funding in the future, with less than 6 months runway.
Penicillin of viruses. Starting phase 2. Long term hold.
Powerful New Weapon Against Bird Flu: NanoViricides' Drug Outperforms Tamiflu in Lab Tests
NanoViricides Engages CRO for Phase II Clinical Trial
Monday, 27th January at 6:30 am
SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE: NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline.
"NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in trea...
No comment yet